Skip Navigation


European Heart Journal Advance Access originally published online on May 7, 2009
European Heart Journal 2009 30(11):1310-1312; doi:10.1093/eurheartj/ehp181
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/11/1310    most recent
ehp181v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Landmesser, U.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Landmesser, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Bone marrow cell therapy after myocardial infarction. What should we select?

Ulf Landmesser*

University Hospital Zurich, Cardiovascular Center, Raemistrassse 100, 8091 Zurich, Switzerland

* Corresponding author. Tel: +41 44 255 9595, Fax: +41 44 255 4251, Email: Ulf.Landmesser@usz.ch

This editorial refers to ‘Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of the randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial’{dagger}, by M. Tendera et al., on page 1313

The first 150 words of the full text of this article appear below.

The promise of a stem/progenitor cell-mediated cardiac repair after myocardial infarction (MI) has fascinated basic scientists and clinical cardiologists alike, and initial small- and intermediate-scale clinical studies have examined the effects of a single intracoronary administration of unfractionated or mononuclear bone marrow cells (BMCs) on left ventricular (LV) function in patients after MI. Several recent meta-analyses of these controlled clinical studies have suggested a moderate, but significant, improvement of LV ejection fraction (EF) by BMC therapy in patients after MI.1,2 The most recent meta-analysis by Martin-Rendon et al. reported an improvement in LVEF of 2.99% in patients undergoing BMC therapy after MI.2 This was close to the observed improvement in LVEF of 2.5% in the REPAIR-AMI (Remodeling in Acute Myocardial Infarction) trial, the largest randomized, controlled clinical study of BMC therapy in patients after MI.3 Although these potential effects of BMC therapy on LV function are less than many investigators . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial
Michal Tendera, Wojciech Wojakowski, Witold Ruzyllo, Lidia Chojnowska, Cezary Kepka, Wieslawa Tracz, Piotr Musialek, Wieslawa Piwowarska, Jadwiga Nessler, Pawel Buszman, Stefan Grajek, Piotr Breborowicz, Marcin Majka, Mariusz Z. Ratajczak, and for the REGENT Investigators (REGENT investigators are listed in the Appendix)
EHJ 2009 30: 1313-1321. [Abstract] [Full Text]